43.95
0.46 (1.06%)
| Previous Close | 43.49 |
| Volume | 681,399 |
| Price / Earnings (Forward) | 38.17 |
| Price / Sales | 11.40 |
| Price / Book | 19.27 |
| 52 Weeks Range |
| Profit Margin | -150.68% |
| Operating Margin (TTM) | -182.26% |
| Diluted EPS (TTM) | -3.01 |
| Quarterly Revenue Growth (YOY) | 7.80% |
| Total Debt/Equity (MRQ) | 481.07% |
| Current Ratio (MRQ) | 5.65 |
| Operating Cash Flow (TTM) | -107.06 M |
| Levered Free Cash Flow (TTM) | -54.76 M |
| Return on Assets (TTM) | -29.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | UroGen Pharma Ltd. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.06 |
|
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 6.87% |
| % Held by Institutions | 105.32% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SCHOENBERG MARK | - | 43.82 | -871 | -38,163 |
| SMITH JASON DREW | - | 43.82 | -1,519 | -66,555 |
| Aggregate Net Quantity | -2,390 | |||
| Aggregate Net Value ($) | -104,718 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 43.82 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SMITH JASON DREW | Officer | 08 Sep 2026 | Sell (-) | 1,519 | 43.82 | 66,555 |
| SCHOENBERG MARK | Officer | 08 Sep 2026 | Sell (-) | 871 | 43.82 | 38,163 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |